Renal Pharmacotherapy
Springer International Publishing (Verlag)
978-3-030-58649-2 (ISBN)
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.
This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.
Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
Larry K. Golightly, PharmD Clinical Research Pharmacist University of Colorado Hospital Aurora, CO 80045 larry.golightly@uchealth.org Isaac Teitelbaum, MD, FACP Professor of Medicine Renal Medicine and Hypertension Section, Division of General Internal Medicine University of Colorado School of Medicine and Director, Home Dialysis Program University of Colorado Hospital Aurora, CO 80045 isaac.teitelbaum@cuanschutz.edu Bonita A. Simendinger, PharmD, BCPS P&T Formulary Compliance Specialist University of Colorado Hospital Aurora, CO 80045 bonita.simendinger@uchealth.org Tyree H. Kiser, PharmD, BCPS, FCCP, FCCM Professor, Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Critical Care Pharmacy Specialist University of Colorado Hospital Aurora, CO 80045 ty.kiser@cuanschutz.edu Gerard R. Barber, RPh, MPH, FASHP Clinical Assistant Professor, Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, CO 80045 gerard.barber@cuanschutz.edu Nancy M. Stolpman, PharmD, PhD Associate Clinical Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Lead Director of Pharmacy UCHealth Aurora, CO 80045 nancy.stolpman@uchealth.org
A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.
| Erscheinungsdatum | 26.09.2021 |
|---|---|
| Zusatzinfo | XXVI, 827 p. 2 illus. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 210 x 279 mm |
| Gewicht | 2541 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Naturwissenschaften ► Chemie ► Technische Chemie | |
| Schlagworte | acute and chronic disease management • Dialysis • dosage management • drug directory • drug elimination • Kidney Disease • Renal impairment • renal pharmacology |
| ISBN-10 | 3-030-58649-9 / 3030586499 |
| ISBN-13 | 978-3-030-58649-2 / 9783030586492 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
